Piper Sandler analyst David Amsellem lowered the firm’s price target on Corcept Therapeutics (CORT) to $121 from $131, owing mainly to slightly lower Korlym estimates and higher SG&A estimates, while keeping an Overweight rating on the shares. The firm notes Corcept reported Q2 diluted EPS of 29c on revenue of $194M, compared to Street estimates of 19c and $199M, respectively.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics price target lowered to $137 from $142 at Canaccord
- Corcept Therapeutics: Buy Rating Backed by Strategic Growth Initiatives and Promising Product Launches
- Corcept Therapeutics Reports Revenue Growth Amid Rising Expenses
- Corcept Therapeutics reports Q2 EPS 29c, consensus 19c
- Corcept Therapeutics Reports Q2 2025 Financial Results